A Study on PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Iranian Hemophilic Patients With Chronic Hepatitis C Infection

Trial Profile

A Study on PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Iranian Hemophilic Patients With Chronic Hepatitis C Infection

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 23 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top